OWLT stock sentiment todayOwlet Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
OWLT
Owlet IncA speculative turnaround play balancing FDA-clearance momentum against a fragile balance sheet and historical de-SPAC volatility.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for OWLT. Not financial advice.
Price · last 12 months
Gossip
The narrative has shifted from 'struggling startup' to 'medical device transition.' Chatter focuses on the 2023 FDA clearance for BabySat, which re-legitimized the brand after regulatory setbacks, though investor fatigue remains high due to long-term price erosion.
- ·FDA clearance for medical-grade pulse oximetry
- ·Expansion into clinical and insurance-reimbursement channels
- ·Retail distribution stability via major players like Amazon and Target
Financial
While revenue growth is recovering and gross margins are improving, the company faces significant liquidity risks and has historically relied on dilutive capital raises to fund operations.
- ·Negative EBITDA and ongoing net losses
- ·High cash burn relative to cash on hand
- ·Improving gross margins nearing 40-45% range
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Potential for further equity dilution to sustain operations
- ·High sensitivity to consumer discretionary spending
- ·Stringent regulatory oversight for medical-grade infant monitoring
Peer temperature
How direct competitors stack up against OWLT right now.
- HOTMASIMasimo Corporation
HOTTER — significantly more robust cash flows and dominant market share in hospital-grade pulse oximetry.
See full analysis → - HOTHIMSHims & Hers Health
HOTTER — higher growth trajectory and superior customer acquisition economics in the telehealth/wellness space.
See full analysis → - COLDUEICUniversal Electronics
COLDER — facing stagnant growth and lack of a high-margin recurring software/subscription narrative compared to Owlet.
See full analysis →
- OWLT-23.0%
- MASI—
- HIMS-7.1%
- UEIC-5.9%
Analyst price target
Consensus average of 3 analysts · median 13.00
Source: StockAnalysis.com · updated 2026-09-23
AI-generated analysis for informational purposes only. Not financial advice.